磷脂酰肌醇蛋白聚糖-3靶向治疗肝细胞癌的研究进展  

Research Progress on Glypican-3 Targeted Therapy in Hepatocellular Carcinoma

作　　者：方宇昕 李育 刘宝姝 董国强 FANG Yuxin;LI Yu;LIU Baoshu;DONG Guoqiang(School of Pharmacy,Naval Medical University,Shanghai 200433,China)

机构地区：[1]海军军医大学药学系,上海200433

出　　处：《药学实践与服务》2023年第10期586-593,共8页Journal of Pharmaceutical Practice and Service

摘　　要：肝癌是全球第二大癌症死亡原因,而肝细胞癌(HCC)是最常见的原发性肝癌形式。磷脂酰肌醇蛋白聚糖-3(GPC3)是一种细胞膜表面蛋白多糖,其在正常成人组织中几乎不表达,但在肝细胞癌中特异性表达上调,因此,GPC3成为肝细胞癌诊断和治疗的可靠靶点。综述了GPC3通过Wnt、YAP、hedgehog等信号通路调节癌症发展,总结了单克隆抗体、双特异性抗体、肿瘤疫苗、免疫毒素、CAR-T细胞、光敏剂治疗等GPC3靶向治疗方法,并对未来基于GPC3的肝细胞癌治疗策略进行展望。Liver cancer is the second leading cause of cancer-related deaths worldwide,with hepatocellular carcinoma(HCC)being the most common form of primary liver cancer.Glypican-3(GPC3)is a cell membrane proteoglycan which is rarely expressed in normal adult tissues but is specifically upregulated in HCC,which makes GPC3 a reliable target for the diagnosis and treatment of HCC.The role of GPC3 in the regulation of cancer development through Wnt,YAP,hedgehog and other signaling pathways were reviewed in this article.GPC3-targeted therapies,such as monoclonal antibodies,bispecific antibodies,tumor vaccines,immunotoxins,CAR-T cells,and photosensitizer therapy were also summarized.These treatment methods offered promising approaches for HCC treatment and future treatment strategies for HCC based on GPC3 were prospected in this paper.

关 键 词：肝细胞癌 磷脂酰肌醇蛋白聚糖-3 信号通路 肝细胞癌治疗 

分 类 号：R735.7[医药卫生—肿瘤]